Journal Mobile Options
Table of Contents
Vol. 45, Suppl. 1, 1996
Issue release date: 1996
Horm Res 1996;45:55–58
Symposium III: Bone Biology and Growth

Biochemical Markers of Bone Turnover

Crofton P.M.a · Stirling H.F.b · Schönau E.d · Ahmed S.F.b · Wallace W.H.B.c · Wade J.C.b · Magowan R.b · Shrivastava A.b · Lyon A.J.b · Mclntosh N.b · Kelnar C.J.H.b
aDepartment of Paediatric Biochemistry, Royal Hospital for Sick Children, bDepartment of Child Life and Health, University of Edinburgh, and cDepartment of Oncology, Royal Hospital for Sick Children, Edinburgh, UK; dChildren’s Hospital, University of Cologne, Cologne, Germany


Three studies to evaluate procollagen type I C-terminal propeptide, type I collagen cross-linked telopeptide and bone alkaline phosphatase (BALP) in the assessment of bone turnover and growth in children are presented. (1) In 50 short normal children treated with placebo or growth hormone, ΔBALP after 3 months of treatment was highly correlated with height velocity response after 1 year (r = 0.67, p < 0.0001). (2) In 12 children with acute lymphoblastic leukaemia, marked changes in collagen peptides, BALP, and lower leg length velocity were seen during the first 6 months of chemotherapy. Suppression occurred during induction and the two intensification phases, with catch-up during the intervening phase (paired t-tests, p < 0.001). (3) Fourteen babies (birthweight < 1,500 g) treated with high-dose dexamethasone for bronchopulmonary dysplasia were compared with 25 non-steroid-treated babies < 1,500 g. Both collagen peptides decreased rapidly and dramatically (mean decreases 41-68%) after dexamethasone was started, accompanied by weight loss and lower leg shrinkage and followed by recovery during steroid weaning.

 goto top of outline Author Contacts

Dr. P.M. Crofton, PhD, Department of Paediatric Biochemistry, Royal Hospital for Sick Children, Sciennes Road, Edinburgh EH9 1LF (UK)

 goto top of outline Article Information

Published online: December 10, 2008
Number of Print Pages : 4

 goto top of outline Publication Details

Hormone Research (From Developmental Endocrinology to Clinical Research)

Vol. 45, No. Suppl. 1, Year 1996 (Cover Date: 1996)

Journal Editor: Czernichow P. (Paris)
ISSN: 0301-0163 (Print), eISSN: 1423-0046 (Online)

For additional information:

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.